Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Temporary Codes for Use with Outpatient Prospective Payment System
C9098 is a valid 2026 HCPCS code for Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose or just “Ciltacabtagene car pos t” for short, used in Medical care.
| HCPCS Level II Code Temporary Codes for Use with Outpatient Prospective Payment System |
|
| HCPCS Code | C9098 |
|---|---|
| Description |
Long description:
Short description: |
| HCPCS Modifier1 | |
| HCPCS Pricing indicator |
53 - Statute
|
| Multiple pricing indicator |
A - Not applicable as HCPCS priced under one methodology
|
| Coverage code | C - Carrier judgment |
| BETOS2 code | O1D - Chemotherapy |
| HCPCS Action code | N - No maintenance for this code |
| Type of service | 1 - Medical care |
| Effective date | Effective Oct 01, 2022 |
| Date added | Added Jul 01, 2022 |
| Termination date | Sep 30, 2022 |
| HCPCS Coding Procedures | |
In HCPCS Level II, modifiers are composed of two alpha or alphanumeric characters.
Example: E0260-NU - Hospital bed, semi-electric (head and foot adjustment), with any type side rails, with mattress
“NU” identifies the hospital bed as new equipment
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”